Cosmo Bio Company,Limited

TSE:3386 Stock Report

Market Cap: JP¥6.5b

Cosmo Bio CompanyLimited Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Cosmo Bio CompanyLimited.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth7.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 12
Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings

Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital

May 09
Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital

Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why

Mar 23
Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why

Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?

Feb 07
Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?

Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?

Jan 17
Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?

Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?

Dec 23
Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?

Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?

Dec 02
Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cosmo Bio CompanyLimited has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSE:3386 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20249,872367N/AN/AN/A
6/30/20249,64233966198N/A
3/31/20249,455408N/AN/AN/A
12/31/20239,340442636736N/A
9/30/20239,303429N/AN/AN/A
6/30/20239,269471538652N/A
3/31/20239,334415N/AN/AN/A
12/31/20229,553517180284N/A
9/30/20229,477576N/AN/AN/A
6/30/20229,507654424528N/A
3/31/20229,400770N/AN/AN/A
12/31/20219,231737507648N/A
9/30/20219,147714N/AN/AN/A
6/30/20218,981714553668N/A
3/31/20218,550775N/AN/AN/A
12/31/20208,092674738803N/A
9/30/20207,821553N/AN/AN/A
6/30/20207,742508829923N/A
3/31/20207,862322N/AN/AN/A
12/31/20197,590237378549N/A
9/30/20197,499317N/AN/AN/A
6/30/20197,257256385603N/A
3/31/20197,113230N/AN/AN/A
12/31/20187,261260768908N/A
9/30/20187,189171N/AN/AN/A
6/30/20187,167156N/A423N/A
3/31/20187,159270N/AN/AN/A
12/31/20177,068237N/A89N/A
9/30/20177,027217N/AN/AN/A
6/30/20177,143261N/A439N/A
3/31/20177,309190N/AN/AN/A
12/31/20167,427254N/A573N/A
9/30/20167,559363N/AN/AN/A
6/30/20167,507342N/A252N/A
3/31/20167,351286N/AN/AN/A
12/31/20157,357230N/A129N/A
9/30/20157,424190N/AN/AN/A
6/30/20157,394163N/A97N/A
3/31/20157,371201N/AN/AN/A
12/31/20147,235201N/A297N/A
9/30/20147,112203N/AN/AN/A
6/30/20147,167310N/A403N/A
3/31/20147,149297N/AN/AN/A
12/31/20137,050313N/A126N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 3386's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if 3386's earnings are forecast to grow faster than the JP market

High Growth Earnings: Insufficient data to determine if 3386's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 3386's revenue is forecast to grow faster than the JP market.

High Growth Revenue: Insufficient data to determine if 3386's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 3386's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 09:36
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cosmo Bio Company,Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution